




PHARMACEUTICAL 2018

MANNKIND CORP
Rank 313 of 342





The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 28% points. The greatest weakness of MANNKIND CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is -254%, being 299% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	57,216
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	87,597
Liabilities, Non-Current	0
Other Assets	437
Other Compr. Net Income	6.0
Other Expenses	30,908
Other Liabilities	211,710
Other Net Income	-9,093
Other Revenues	11,745
Property and Equipment	26,922
Research and Development	14,118
Selling, General and Administrative Expense	74,959

Output Variable	Value in 1000 USD
Assets	84,575
Liabilities	299,307
Expenses	119,985
Revenues	11,745
Stockholders Equity	-214,732
Net Income	-117,333
Comprehensive Net Income	-117,330
Economic Capital Ratio	-254%